Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Recently, Aibo biology and Jiahe biology jointly announced that they have reached a cooperative development agreement. The two sides will jointly develop globally innovative mRNA products and related drugs. Based on the Jiahe biological antibody development platform and the mRNA technology platform of Aibo biology, the two sides will cooperate in the exploration and research of mRNA drugs for tumor treatment.
This is another important cooperation between Aibo biology and newforce after reaching a strategic partnership to jointly carry out the new drug research and development project of lipid nanoparticles (LNP) mRNA delivery for the treatment of retinal diseases, which further demonstrates the development strength of the platform company.
This text is a result of machine translation.
Briefing Feb 07, 2023 12:11 PM
· Healthcare
ForLong Biotech Nets Over CNY 100 Mn in Series A
Briefing Feb 07, 2023 10:59 AM
· Healthcare
CytoCan Corp. Nets CNY 10 Mn in Seed Round
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Briefing Jan 30, 2023 10:44 AM
· Healthcare
Levostar Completes Pre-A Financing Round to Further Invest in CGT
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Jun 23, 2022 10:20 AM
· Healthcare
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Briefing Jun 23, 2022 10:15 AM
· Healthcare
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
See more
Read next
Insight
In-depth
Insight
In-depth